We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

First US Trial Participant Receives Gimsilumab for COVID-19 and Acute Respiratory Distress Syndrome

News   Apr 16, 2020 | Original story from Temple Health

 
First US Trial Participant Receives Gimsilumab for COVID-19 and Acute Respiratory Distress Syndrome
 
 
Advertisement
 

RELATED ARTICLES

Disruption of Lung Biological Clock in Premature Infants May Raise Later Flu Risk

News

Disruptions in the circadian rhythms in lung cells may explain why adults who survived premature birth are often more at risk of severe influenza infections, suggests a study in mice published in eLife.

READ MORE

Study Reveals How SARS-CoV-2 Infects Heart Cells

News

A new study provides evidence that COVID-19 patients' heart damage is caused by the virus invading and replicating inside heart muscle cells, leading to cell death and interfering with heart muscle contraction.

READ MORE

Food Ingredient Sesaminol Alleviates Parkinson’s Symptoms in Mice

News

Researchers have discovered that the waste from sesame seed oil production has an abundance of a chemical called sesaminol, which has protective effects against Parkinson's disease.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE